The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Inclusion criteria

• Patients with advanced malignant tumor confirmed by histology or pathology, failed by standard treatment, no standard treatment or no standard treatment is applicable;
• Eastern Cooperative Oncology Group (ECOG) 0 or 1;
• Life expectancy ≥ 12 weeks;
• At least one measurable lesion according to RECIST 1.1;
• Adequate organ function;

Exclusion criteria

• central nervous system metastasis；
• There is a pleural, abdominal or pericardial effusion that is clinically symptomatic or requires repeated management (puncture or drainage, etc.)；
• Images in screening showed that the tumor surrounded important blood vessels or had obvious necrosis and voids, and the investigators believed that it might cause bleeding risk；
• The presence of severe, unhealed or open wounds, active ulcers, or untreated fractures；
• A history of significant bleeding tendency or severe coagulopathy；
• The presence of poorly controlled hypertension；